Anaveon announces presentation of a novel development compound at the 2023 American Association for Cancer Research Annual Meeting BASEL, Switzerland, March 23, 2023 (GLOBE NEWSWIRE) -- Anaveon, a clinical stage, immuno-oncology company, today announced that it will present a poster on ANV600 at the American Association for...

Anaveon presents updated data from the Phase I/II study of ANV419 during the ESMO Congress 2022 - ANV419 is well-tolerated at high doses and demonstrates notable safety with strong pharmacodynamic effects and excellent IL-2Rbg selectivity – - A Phase II program of ANV419 has been initiated in...

Anaveon presents compelling data from the Phase I/II study of ANV419 during the AACR Annual Meeting 2022 - ANV419 is very well-tolerated and demonstrates exceptional safety with strong pharmacodynamic effects and excellent IL-2Rβγ selectivity - - A Phase II program of ANV419 has been initiated in...

Anaveon to raise CHF 110 million in oversubscribed Series B financing - Leading international syndicate led by Forbion and corner-stoned by founding investor Syncona- Confirms depth of support for Anaveon’s approach to developing engineered cytokines in multiple...